Atamyo Therapeutics is focused on the development of a new generation of safe and effective gene therapies for neuromuscular diseases. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD). The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Evry, 91000, Fr
- Industry
- Biotechnology
- Website
- https://www.atamyo.com
- Keywords
- Gene Therapy, Neuromuscular diseases, Muscle distrophy, LGMD-R9/2I, LGMD, LGMD-R5/2C, LGMD-R1/2A, LGMD-R3/2D, LGMD6R2/2B.
- HQ
- Evry
Atamyo Therapeutics Questions
Atamyo Therapeutics's website is https://www.atamyo.com
Atamyo Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/atamyo-therapeutics
Atamyo Therapeutics has
4 employees.
View email and phone details for 4
employees at Atamyo Therapeutics.
Atamyo Therapeutics's industry is
Biotechnology
Atamyo Therapeutics's top competitors are
Stoke Therapeutics,
Gensight Biologics,
Genethon,
Andelyn Biosciences,
Nvelop Therapeutics,
Capricor Therapeutics, Inc.,
Replicate Bioscience, Inc.,
Modalis Therapeutics,
Ptc Therapeutics, Inc.,
The Dion Foundation.
Atamyo Therapeutics's categories are Biotechnology
Atamyo Therapeutics's founding year is 2020
